Brands
Kiran Mazumdar-Shaw names Claire Mazumdar as successor at Biocon
Next-gen leadership takes shape as biotech founder signals future transition
MUMBAI: Kiran Mazumdar-Shaw, founder of Biocon, has named her niece Claire Mazumdar as her successor, according to media reports, signalling a generational shift at one of India’s leading biotech firms.
Claire Mazumdar, 37, is currently chief executive officer of Bicara Therapeutics, where she has been leading the company since January 2020 from its base in Cambridge, Massachusetts. Her role has focused on advancing clinical-stage oncology programmes and scaling operations in a competitive biotech landscape.
Before taking the helm at Bicara, she led business development and corporate strategy at Rheos Medicines, building experience in deal-making and strategic partnerships. She has also worked with Third Rock Ventures, a well-known biotech investment firm.
Claire currently serves on the board of directors at Relay Therapeutics, where she is also part of the audit committee, and at Noora Health, reflecting a blend of commercial and social sector engagement.
Academically, she brings strong credentials, holding an MBA from Stanford University Graduate School of Business and a PhD in cancer biology from Stanford University School of Medicine.
While no formal timeline for the transition has been announced, the reported move indicates early succession planning at Biocon, with Claire Mazumdar emerging as a key figure in shaping the company’s next phase.
If confirmed, the leadership transition would mark a notable moment for India’s biotech sector, blending legacy with fresh global experience as Biocon looks to expand its footprint in innovation-driven healthcare.
